Research on the cell biology of tumors. Covers cancer-cell vulnerabilities, tumor spread, nanoreactor therapies, and AI-guided cancer research.
Researchers at Buck Institute discover non-invasive biomarker test to measure and track performance of senolytic drugs, which target multiple age-related diseases. The biomarker detects a unique lipid metabolite released when senescent cells die.
A new molecular pathway discovered in fruit flies helps steer moving cells towards specific destinations, which may drive cancer cells to metastasize. The pathway involves a series of proteins and enzymes that work together to control cell movement, offering potential targets for interrupting cancer cell spread.
Researchers have developed an AI-based software called 3DeeCellTracker, which can automatically track cells in 3D microscope videos. This versatile tool enables the analysis of cellular activities across biology, medical research, and drug development.
A new study reveals that human and mouse cancer cells use specific mechanisms to survive heat shock and regain their original function. The research, published in Molecular Cell, identified key genes involved in the process, including those related to autophagy and RNA processing.
Scientists from UNIGE discovered that paxillin helps cells perceive their environment and dock at the right place using cellular crampons. Without functional paxillin, cells can't attach properly and slip continuously.
A new method makes it possible to accurately show whether the number of cancerous cells in the bone marrow is increasing in a patient with multiple myeloma. This blood test could potentially replace the current bone marrow puncture, enabling quicker treatment initiation.
A new method developed by researchers at the University of Missouri uses machine learning to analyze large amounts of biological data from single-cell RNA-sequencing. This allows scientists to identify patterns and make faster conclusions, which can lead to potential treatments for diseases such as Alzheimer's.
Researchers at Kumamoto University found that aging cells in abdominal fluid contribute to peritoneal dissemination of gastric cancer by promoting cellular senescence and inflammation. This understanding could lead to new treatments targeting cancer cells and associated fibroblasts.
Researchers at Cold Spring Harbor Laboratory have discovered how human cells assemble and disassemble Origin Recognition Complexes to initiate DNA replication. The study reveals a specific interaction between ORC1 protein and CDC6, allowing them to work together in a coordinated manner.
A study analyzing 45 patients with Merkel cell carcinoma found that patients with shorter disease-free intervals and specific genetic mutations, such as ARID2 and NTRK1, may be more likely to benefit from immunotherapy. These findings could inform treatment decisions and future research.
Researchers at Nara Institute of Science and Technology have discovered a way for cells to communicate using filopodia, small finger-like projections. Filopodia-derived extracellular vesicles promote wound closure by sending cellular signals that encourage cell migration.
A new technique for sampling and testing cells from Barrett's esophagus patients can detect specific chromosomal alterations, including the presence of esophageal adenocarcinoma. The approach combines esophageal brushing with massively parallel sequencing to provide an accurate assessment of disease stages and identify high-risk patients.
Researchers have discovered that ADAR1 can bind to multiple forms of RNA, leading to the misregulation of the immune response in cancer. This finding has implications for the development of new therapies targeting ADAR1's role in cancer regulation and other diseases.
Researchers discovered pancreatic cancer cells employ macropinocytosis, a novel pathway to procure nutrients when autophagy is inhibited, enabling them to thrive despite starvation. A combination of autophagy and macropinocytosis inhibitors resulted in rapid tumor regression in mouse models.
Researchers from Max Planck Institute of Molecular Physiology have developed a cell-based assay that identifies highly potent IDO1 inhibitors with different mechanisms of action, which could lead to promising immunotherapies for cancer treatment. The new approach overcomes limitations of existing cell-free assays and holds promise for ...
Researchers developed acid-sensitive nanoparticles that can penetrate dense stromal barriers and eliminate cancerous cells. The approach may offer a new avenue for developing efficacious drugs inhibiting pancreatic tumor growth and metastasis.
Researchers developed a method to identify single cancer cells using machine learning and pH-sensitive dye bromothymol blue. The technique can discriminate between healthy and cancerous cells, as well as different types of cancer, without inducing toxic effects or killing the cell.
A novel technique using artificial intelligence can distinguish between healthy and cancerous cells by analyzing their pH level. This method allows for fast and accurate cancer diagnosis, with single-cell classification accuracy rates of over 95%.
A novel HIPK2 isoform is identified that promotes YAP/TEAD transcriptional activity in non-small cell lung cancer cells. The study suggests that this isoform may play an oncogenic role in NSCLC and could be a potential therapeutic target.
The ADAR1p110 isoform regulates genome stability at chromosome ends, preventing R-loop accumulation and preserving telomere stability. In cancer cells, depletion of ADAR1p110 leads to extensive telomeric DNA damage and arrested proliferation.
Researchers at Harvard University have designed a new highly-selective tool to study proteins that are difficult to target with drugs, known as 'undruggable' proteins. The tool uses a nanobody to add or remove specific sugars from proteins, providing a detailed understanding of their function.
Researchers used an experimental safety switch to curb treatment side effects in a patient with refractory acute B-cell leukemia, achieving a significant reduction in toxicities. The study demonstrates potential for expanded use of CAR-T immunotherapy paired with the safety switch.
Researchers develop targeted immunotherapy approach that specifically kills cancer cells by targeting mutant protein fragments presented on the cell surface. The therapy uses bispecific antibodies to recognize and destroy cancer cells, bypassing conventional antibody limitations.
Scientists at Far Eastern Federal University have developed a compound that kills prostate cancer cells while also activating an enzyme protecting them. The compound, 3,10-dibromofascaplysin, works well in combination with approved anticancer drugs and is being studied for its potential to reduce side effects.
Researchers develop bispecific T-cell engaging antibodies that target cancer cells and stimulate the immune system without removing T-cells. This approach could make personalized treatments more broadly accessible and potentially transform cancer into a chronic disease.
Researchers discovered artificial microswimmers slow down and accumulate in low-fuel regions where their speed is minimized. This finding suggests a new strategy to improve targeted cancer therapy by delivering chemotherapy drugs to the most problematic cells.
Researchers have discovered a gene called ENDU-2 that can trigger tumor formation from a distance while also protecting cells under stress. In the nematode worm C. elegans, ENDU-2 helps protect germline immortality, suggesting its role in cancer development and cell survival.
Researchers develop a new protein, 161519 TriKE, to target cold tumors and enhance the immune response. The study found that 161519 TriKE successfully reduced tumor growth and increased overall survival in tumor-bearing mice.
Researchers have successfully 'caught' colibactin, a genotoxin from E. coli, inducing genetic changes characteristic of colorectal cancer cells. This breakthrough enables the observation of transformation in vitro using human colon organoids.
Researchers studied cell interactions in a microscopic 'cell collider' and found that normal cells repel each other's protrusions, while cancer cells try to squeeze past each other. The study suggests new approaches for understanding cancer cell behavior and identifying molecular bases for these differences.
A study published in Oncotarget found that hemoglobin-based oxygen carriers increase chemotherapy effectiveness in non-small cell lung cancer. PolyHb administration attenuates tumor growth without alleviating hypoxia, suggesting a potential strategy to enhance cisplatin sensitivity.
A study published in Cell Death & Disease found that inhibiting the EZH2 protein can reduce cancer cell growth in multiple myeloma. The researchers discovered that certain metabolic pathways are altered in cells sensitive to EZH2 inhibition, providing potential markers for treatment response.
Researchers at Lund University discovered how E. coli bacteria target and degrade the MYC oncogene, a well-known contributor to many forms of cancer. This discovery has shown potent effects on tumor growth and increased survival in two different cancer models.
Research on T cells reveals that prolonged exposure to antigens can lead to exhaustion, reducing their ability to contribute to immune responses. A new model study identifies dynamic adjustments in T helper cells' states of exhaustion and suggests potential therapeutic targets.
Researchers developed a new strategy to destroy cancer cells using magnetic nanoparticles and constant magnetic fields. The combined effect of nanoparticles and magnetic fields reduced the viability of leukemia cells while sparing healthy cells, suggesting a selective therapeutic effect.
Researchers at University of Helsinki discovered a molecular mechanism that promotes cell migration by recycling actin filaments. Twinfilin efficiently removes Capping Protein from filament plus-ends, leading to depolymerization and slower cell migration in its absence.
The study shows that the BAF complex plays a crucial role in controlling DNA accessibility and that its inhibition leads to rapid changes in chromatin structure. This has significant implications for understanding cancer development and identifying potential therapeutic targets.
A new synthetic gene circuit process allows for more effective disease treatment by preventing cancer cells from metastasizing and making them receptive to treatment. The technology, developed at Arizona State University, has broad implications for improving the effectiveness of various disease therapies.
Researchers at Technion-Israel Institute of Technology have discovered a new pathway that targets cancer cells specifically, minimizing damage to healthy cells. The folate cycle is essential for DNA and RNA production, and the team found that tumor cells relying on the cytosolic pathway are more susceptible to targeted treatments.
The study investigates the role of cell cycle progression on analyzing telomerase activity in cancer cells based on an AIEgen-based fluorescence detecting system. The results show that cancer cells exhibit increased fluorescence intensity during different stages of the cell cycle, while normal cells do not.
Researchers at the Max Delbrück Center used advanced microscopy to determine that CXCR4 receptor on cancer cells appears in both transient pairs and alone, depending on receptor density. This knowledge may lead to more effective cancer drugs with fewer side effects.
Researchers at the University of Seville have solved a long-standing enigma in basic biology by discovering how lipids distribute proteins within cells. Using a new microscopy technology, they found that membrane lipids select and direct specific proteins to correct exit doors.
Researchers have identified a key function of AIM2, a molecule that plays a vital role in regulating the adaptive immune system. The study reveals that AIM2 is expressed at higher levels in regulatory T cells, which prevent overzealous immune responses and mitigate autoimmune diseases.
Researchers develop innovative approach to treating bone tumors by starving cancer cells of their energy source, potentially replacing toxic chemo with a less harmful treatment. The two-drug combination showed promise in mice studies, outperforming a commonly used chemotherapy drug without severe side effects.
Researchers used XSEDE Stampede2 supercomputer to simulate polarized elongation of actin filaments, shedding light on their polymerization kinetics. The study's findings have potential applications in cancer treatment and development of self-healing materials.
A new method has been developed to identify peptides that inhibit histone deacetylases (HDACs), enzymes that play a role in cancer development and treatment. The researchers hope to use this method to develop more specific HDAC inhibitors with fewer side effects, leading to improved cancer therapy.
Researchers at Northwestern University have developed a novel therapy that uses synthetic nanoparticles to trigger the destruction of lymphoma cells by depriving them of cholesterol. This approach has potential for targeting other cancers with an appetite for cholesterol, such as kidney and ovarian cancer.
Researchers at Toyohashi University of Technology developed a low-cost method for intracellular delivery using titanium-oxide nanotubes and nanosecond pulse lasers. The study successfully delivered propidium iodide and fluorescent dextran into HeLa cells with high efficiency and cell viability.
Scientists have discovered a previously unknown enzymatic function of the Epstein-Barr Virus (EBV) protein EBNA1, which could lead to new approaches for treating EBV-associated cancers. The study sheds light on how this protein helps replicate and maintain the viral genome in infected cells.
Using CRISPR, scientists have created 'scratchpad' cells that can be tracked in real-time as they proliferate and spread. This method reveals differences in tumor biology and identifies genes associated with metastasis.
Researchers at Sloan Kettering Institute found a new link between Warburg metabolism and PI3 kinase activity, challenging the long-held view that metabolism is secondary to cell signaling. The study suggests targeting metabolism could be an effective way to curb cancer growth.
A new method traces real-time cancer progression across thousands of cells, identifying rare events and distinct gene expression profiles associated with metastatic phenotypes. The approach could inform aspects of cellular cancer biology, including genetic mutations, microenvironment adaptation and resistance to therapeutic agents.
Researchers at Moffitt Cancer Center discovered that cancer cells can fuse and recombine their genetic material, leading to increased diversity and adaptability. This mechanism, similar to parasexual recombination in pathogenic microbes, enables cancer cells to rapidly evolve and acquire resistance to treatments.
A new method, D2O-CANST-R, allows for rapid and precise tracking of metabolic changes in cancer cells at the single-cell and single-organelle level. This approach has the potential to reveal the metabolism in a cancer cell with very fine details and distinguish between effective and ineffective drugs.
Cell velocity depends on surface stickiness, and researchers have figured out the precise mechanics. A mathematical model captures forces involved in cell movement, matching experimental results for various cell types. The findings could provide new targets to interrupt tumor metastasis.
Researchers from UC3M and UCM developed a mathematical model to understand how cancer cells invade healthy tissue, using topological data analysis techniques. The model simulates the collective movement of cells in tissues and can be used to track the progression of tumor growth.
Researchers created nanodiamond sensors that can act as both heat sources and thermometers, allowing for the measurement of thermal conductivity inside living cells. This breakthrough may lead to new diagnostics tools and cancer therapies, as well as a better understanding of metabolic disorders such as obesity.
Researchers at UNH discovered a new inhibitor drug combination that effectively reduces growth and kills WM cancer cells, offering more treatment options. Adding venetoclax or panabinostat to BET inhibitors shows improved efficacy in treating Waldenström macroglobulinemia.
Researchers at Moffitt Cancer Center have identified a novel biochemical pathway that protects cells from ferroptosis, a type of cell death caused by oxidation imbalance. The discovery involves the activation of the protein GCLC, which leads to the production of gamma-glutamyl-peptides that shield cells against ferroptosis.
Researchers discovered that ovarian cancer cells undergo structural changes in their mitochondria to survive and proliferate in the peritoneal cavity. This adaptation enables aggressive cancerous cells to grow and spread, making it harder to detect and treat. Understanding these cellular adaptations could lead to new targeted therapies.